ClinicalTrials.gg

Program

HY6725

A development code.

Its studies are led by Newsoara Biopharma.

Furthest: phase 1, since Nov 19, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newsoara Biopharma11 open or runningphase 1since Nov 19, 2025Nov 19, 2025Mar 2027phase 1 · NCT07262281

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2025First study: phase 1 study in HealthyFirst studyNCT07262281 · 74 planned · Australia

Ahead

  1. Mar 2027Primary completion: phase 1 study in HealthyNCT07262281

TargetBeta

IL33 →TSLP →read by rule
“The rationale of the study is HY6725 is a novel, fully human monoclonal antibody engineered to simultaneously neutralize human TSLP and IL-33.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07262281Healthy · Australia1RecruitingMar 202774

How it is read

Names in the registry

  • “HY6725”, 1 entry

Codes read as this program: HY6725.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.